Liquid Biopsy with 3D Genomic Biomarkers as a Clinical Tool For Diagnosis, Prognosis & Disease Understanding in ALS

Time: 8:30 am
day: Conference Day One Morning


  • 3D Genomic EpiSwitch® blood-based biomarkers: development of bloodbased clinical tests for early diagnosis, prognosis and prediction of response to treatment
  • ALS diagnostic and prognostic EpiSwitch® tests: from development to deployment in MTPA Radicava trial
  • EpiVerseTM profiling of ALS regulatory 3D genomic footprint: from ALS subtypes to neuro-inflammation and strong predictors as therapeutic targets